SECOND AMENDMENT TO PROJECT AGREEMENT No. 2 BETWEEN VIROPHARMA INCORPORATED AND NORWICH PHARMACEUTICALS, INC. (Formerly OSG Norwich Pharmaceuticals, Inc.) (Vancocin® HCl capsules) SECOND AMENDMENT TO PROJECT AGREEMENT No. 2

Exhibit 10.2

Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

SECOND AMENDMENT TO

PROJECT AGREEMENT No. 2

BETWEEN

VIROPHARMA INCORPORATED

AND

NORWICH PHARMACEUTICALS, INC.

(Formerly OSG Norwich Pharmaceuticals, Inc.)

(Vancocin^® HCl capsules)

SECOND AMENDMENT TO PROJECT AGREEMENT No. 2

VIROPHARMA INCORPORATED (“ViroPharma”) and NORWICH PHARMACEUTICALS, INC. (formerly known as OSG Norwich Pharmaceuticals, Inc.) (“NPI”) are entering into this Second Amendment to Project Agreement No. 2 (this “Second Amendment”) effective as of the 25^th day of May, 2011.

This Second Amendment amends that certain Project Agreement No. 2 between ViroPharma and NPI dated May 15, 2006, as amended (“Project Agreement No. 2”) entered into pursuant to the Master Agreement (the “Agreement”) and the Quality Agreement (the “Quality Agreement”) between ViroPharma and NPI dated as of December 1, 2005. The Second Amendment described herein relates to the extension of the term of Project Agreement No. 2 and changes to the fee structure if an abbreviated new drug application for a generic version of the Product is approved, and shall be governed by the terms, conditions and obligations set forth in the Agreement, the Quality Agreement, Project Agreement No. 2, as previously amended, and this Second Amendment. Terms not otherwise defined herein are set forth in the Project Agreement No. 2 and the Agreement. In consideration of the mutual covenants and agreements contained herein, ViroPharma and NPI, intending to be legally bound, do hereby agree as follows:

1. Amendment of Section 1. Section 1(f) is hereby deleted in its entirety and replaced with the following:

2. Amendment of Section 5. Section 5 is hereby amended by adding the following at the end of the section:

“Notwithstanding anything to the contrary in this Agreement, NPI shall not ***the***, *** or *** in*** or ***.”

3. Amendment of Section 7. Section 7 is hereby deleted in its entirety and replaced with the following:

This Project Agreement shall be effective as of the Project Agreement Effective Date and shall expire at the end of the Initial Term. At the end of the Initial Term, this Project Agreement shall continue automatically for successive one (l) year periods under the same terms and conditions hereunder until terminated (each such period a “Renewal Term” and collectively with the Initial Term, the “Term”). This Project Agreement may be terminated by ViroPharma at any time upon not less than *** months prior written notice to NPI. NPI may terminate this Project Agreement at the expiration of the Initial Term or the expiration of any renewal term upon not less than *** months prior written notice to ViroPharma. In addition to the foregoing, either Party may terminate this Project Agreement in the event of a material breach by the other Party of this Project Agreement, provided that the Party asserting such breach first serves written notice of the alleged breach on the offending Party and such

breach is not cured within *** days of said notice; provided further, however, that this Project Agreement shall not terminate in the event of a material breach pursuant to this Section 7 unless, at the termination of such *** day period, the Party asserting such breach notifies the other Party in writing of such termination due to a failure to cure the material breach.

4. Amendment of Section 9. Section 9 is hereby amended by adding the following as subsection (i):

2

5. Amendment of Price Exhibit. The Price Exhibit is hereby amended by deleting the two tables under “MANUFACTURING PRICE” and replacing them with the following:

(a) The revised Manufacturing Price set forth in the amended Price Exhibit above shall be effective as of January 1, 2011. NPI may invoice ViroPharma for the difference between (i) the revised Manufacturing Price set forth in the amended Pricing Exhibit above and (ii) the Manufacturing Price previously invoiced by NPI to ViroPharma for orders on or after January 1, 2011.

(b) Project Agreement No. 2, as previously amended, shall remain in full force and effect, subject only to the express changes set forth in this Second Amendment, and the parties hereto hereby ratify and confirm the provisions of the Project Agreement No. 2, as so modified. Project Agreement No. 2, as supplemented and modified by this Project Agreement Amendment, constitutes the entire understanding between the parties with respect to the subject matter thereof, and supersedes any prior understanding and/or written or oral agreements among them. This First Amendment may not be changed, modified, discharged or terminated orally or in any manner other than by an agreement in writing signed by the parties hereto. All references to “this Project Agreement” in the Project Agreement No. 2 shall mean Project Agreement No. 2 as modified hereby and from time to time hereafter. This Project Agreement Amendment may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one instrument.

(c) Governing Law. This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania excluding any choice of law rules, which may direct the application of the law of another state.

3

(d) As noted above, this Second Amendment is subject to the terms and conditions of, among other agreements, the Agreement, including but not limited to Section 18.1 of the Agreement.

IN WITNESS WHEREOF, the Parties have caused this Project Agreement Amendment to be executed and delivered on the date first set forth above.

4